| 1. | jcacrmn | |
| 2. | teckback | |
| 3. | hgresser | |
| 4. | bigwhit244 | |
| 5. | grummananan |
Top Board Researchers
These are the top researchers based on quality of posts as voted by board members. Typically they know their stuff and are a great
way to catch up on what the company is all about.
HOW DO I BECOME ONE?
Just do great research! As other members approve of your posts, you earn points that move you up the ranks.| 1. | hgresser 02/06/2018 Where Is Synergy Pharmaceuticals Inc Heading From Here? H.C. Wainwright Weighs In - Smarter Analyst |
| 2. | bigwhit244 05/15/2018 Synergy Pharmaceuticals (SGYP): Can Trulance Uptake Grow Stronger? Oppenheimer and Cantor Weigh in |
| 3. | jcacrmn 05/10/2018 Synergy Pharmaceuticals (SGYP) Stock Sinks on Disappointing Earnings Update |
| 4. | teckback 01/25/2018 Announces FDA approval of TRULANCE (Plecanatide) for the treatment of irritable bowel syndrome with constipa… |
| 5. | teckback 05/11/2018 Synergy Pharmaceuticals Reports First Quarter 2018 Financial Results and Business Update |
| 6. | jcacrmn 01/25/2018 Great news today! - Cantor Fitzgerald reiterates Buy rating, $10 PT |
| 7. | jcacrmn 02/01/2018 Big news out... - H.C. Wainwright & Co. reiterates Buy rating, $7 PT |
| 8. | teckback 05/07/2018 H.C. Wainwright & Co. sets PT at $7 |
| 9. | hgresser 01/25/2018 Synergy Pharmaceuticals Inc Enters a Fiercely Competitive IBS-C Market, But |
| 10. | teckback 01/09/2018 Synergy Pharmaceuticals Inc (SGYP) Savvy Leadership Turnover and Upcoming Trulance Approval in IBS-C Have This Bull Confident |
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW
Synergy Pharmaceuticals, Inc.
- SGYP
- Public Stock Message Board
Filtering by:
-
To use your chart in a post, click the
icon above the chart. From there you can get the chart link or download the image.